A double-blind, placebo controlled, randomized, cross-over polysomnographic study of MK0928 [gaboxadol] 15 mg in adult patients with primary insomnia

Trial Profile

A double-blind, placebo controlled, randomized, cross-over polysomnographic study of MK0928 [gaboxadol] 15 mg in adult patients with primary insomnia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2015

At a glance

  • Drugs Gaboxadol (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 23 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top